Sameer Mirza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11758946/publications.pdf

Version: 2024-02-01

37 papers	1,372 citations	331670 21 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	2137 citing authors

#	Article	IF	Citations
1	Ecdysoneless Protein Regulates Viral and Cellular mRNA Splicing to Promote Cervical Oncogenesis. Molecular Cancer Research, 2022, 20, 305-318.	3.4	6
2	The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export. Molecular and Cellular Biology, 2021, 41, e0010321.	2.3	6
3	Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer. Cancers, 2020, 12, 2838.	3.7	5
4	Pan-Cancer Analysis Reveals the Diverse Landscape of Novel Sense and Antisense Fusion Transcripts. Molecular Therapy - Nucleic Acids, 2020, 19, 1379-1398.	5.1	30
5	Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Research, 2018, 78, 2524-2535.	0.9	35
6	3D hydrogel breast cancer models for studying the effects of hypoxia on epithelial to mesenchymal transition. Oncotarget, 2018, 9, 32191-32203.	1.8	43
7	3D Bioprinting of Breast Cancer Models for Drug Resistance Study. ACS Biomaterials Science and Engineering, 2018, 4, 4401-4411.	5.2	104
8	Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway. Cell Cycle, 2017, 16, 1515-1525.	2.6	15
9	Mammalian ECD Protein Is a Novel Negative Regulator of the PERK Arm of the Unfolded Protein Response. Molecular and Cellular Biology, 2017, 37, .	2.3	7
10	Acetylation of Mammalian ADA3 Is Required for Its Functional Roles in Histone Acetylation and Cell Proliferation. Molecular and Cellular Biology, 2016, 36, 2487-2502.	2.3	13
11	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Research and Treatment, 2016, 159, 457-467.	2.5	22
12	ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. Breast Cancer Research, 2016, 18, 113.	5.0	10
13	A Novel Interaction of Ecdysoneless (ECD) Protein with R2TP Complex Component RUVBL1 Is Required for the Functional Role of ECD in Cell Cycle Progression. Molecular and Cellular Biology, 2016, 36, 886-899.	2.3	19
14	Mutant PIK3CA Induces EMT in a Cell Type Specific Manner. PLoS ONE, 2016, 11, e0167064.	2.5	5
15	The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells. Cell Cycle, 2015, 14, 990-1000.	2.6	9
16	The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 2015, 150, 91-103.	2.5	10
17	Alteration/Deficiency in Activation 3 (ADA3) Protein, a Cell Cycle Regulator, Associates with the Centromere through CENP-B and Regulates Chromosome Segregation. Journal of Biological Chemistry, 2015, 290, 28299-28310.	3.4	10
18	Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. Breast Cancer Research and Treatment, 2013, 137, 721-731.	2.5	15

#	Article	IF	Citations
19	Expression of DNA Methyltransferases in Breast Cancer Patients and to Analyze the Effect of Natural Compounds on DNA Methyltransferases and Associated Proteins. Journal of Breast Cancer, 2013, 16, 23.	1.9	186
20	Abstract B120: Ada3, a component of ATAC complex is involved in regulation of the Genomic stability, DNA repair process and breast cancer. , 2013, , .		0
21	Mammalian Alteration/Deficiency in Activation 3 (Ada3) Is Essential for Embryonic Development and Cell Cycle Progression. Journal of Biological Chemistry, 2012, 287, 29442-29456.	3.4	27
22	Alteration/deficiency in activation-3 (Ada3) plays a critical role in maintaining genomic stability. Cell Cycle, 2012, 11, 4266-4274.	2.6	28
23	DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumor Biology, 2012, 33, 1837-1843.	1.8	42
24	Clinical Significance of Promoter Hypermethylation of ERÎ² and RARÎ²2 in Tumor and Serum DNA in Indian Breast Cancer Patients. Annals of Surgical Oncology, 2012, 19, 3107-3115.	1.5	29
25	Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. Breast Cancer Research and Treatment, 2012, 134, 171-180.	2.5	21
26	Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumor Biology, 2011, 32, 23-32.	1.8	33
27	Mouse models of estrogen receptor-positive breast cancer. Journal of Carcinogenesis, 2011, 10, 35.	2.5	31
28	Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Molecular and Cellular Biochemistry, 2010, 342, 101-109.	3.1	55
29	CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clinical Biochemistry, 2010, 43, 373-379.	1.9	59
30	Clinical significance of Stratifin, ERÎ± and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clinical Biochemistry, 2010, 43, 380-386.	1.9	38
31	Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sciences, 2010, 87, 83-91.	4.3	79
32	Prognostic Relevance of Promoter Hypermethylation of Multiple Genes in Breast Cancer Patients. Analytical Cellular Pathology, 2009, 31, 487-500.	1.4	4
33	Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cellular Oncology, 2009, 31, 487-500.	1.9	34
34	Epigenetic alterations of CDH1 and APC genes: Relationship with activation of Wnt/Î²-catenin Pathway in invasive ductal carcinoma of breast. Life Sciences, 2008, 83, 318-325.	4.3	86
35	Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sciences, 2007, 80, 1873-1881.	4.3	90
36	Promoter hypermethylation of TMS1, BRCA1, ERÎ± and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sciences, 2007, 81, 280-287.	4.3	101

#	Article	IF	Citations
37	Detection of RASSF1A and RAR? Hypermethylation in Serum DNA from Breast Cancer Patients. Epigenetics, 2006, 1, 88-93.	2.7	65